Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sunesis Pharmaceuticals Inc (NASDAQ:SNSS)

3.09
Delayed Data
As of May 26
 +0.02 / +0.65%
Today’s Change
2.76
Today|||52-Week Range
6.30
-14.64%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$66.3M

Company Description

Sunesis Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The company's primary activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Sunesis Pharmaceuticals was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Contact Information

Sunesis Pharmaceuticals, Inc.
395 Oyster Point Boulevard
South San Francisco California 94080
P:(650) 266-3500
Investor Relations:

Employees

Shareholders

Mutual fund holders5.28%
Other institutional41.77%
Individual stakeholders0.62%

Top Executives

Daniel N. SwisherPresident, CEO, CFO, Secretary & Director
Gene C. JamiesonVice President-Technical Operations
Jennifer A. SmithVice President-Biometrics
Parvinder S. HyareVice President-Global Oncology Operations
Deborah A. ThomasSenior VP-Regulatory Affairs, Quality Assurance